The downturn comes as the head of drugmaker Moderna (MRNA) told the Financial Times that COVID-19 vaccines are unlikely to be as effective against the Omicron variant as they have been against the Delta strain.
“I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . . are like, ‘This is not going to be good’.”